Get notified when ATTO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (new) — The company discloses that identifying material weaknesses in internal controls could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of its consolidated financial statements.
- Wuxi Apptec (new) — A key contract manufacturer, WuXi AppTec, was designated on the 1260H List on June 8, 2026, which could lead to restrictions under the BIOSECURE Act and disrupt supply.
- Biosecure Act (new) — The company relies on Chinese CMOs, and the BIOSECURE Act could restrict its ability to work with them, potentially disrupting supply.
ATTO prices $289M IPO at $17/share; clinical-stage biotech to net $265.1M for pipeline
Filed August 5, 2026 · ~2 min read
Key Changes
-
high
ATTO is offering 17,000,000 shares at $17.00 per share, raising $289.0M gross; net proceeds to the company are $265.1M.
The Offering verify on EDGAR → -
high
The company plans to use $110-130M for ATTO-1310 Phase 2, $60-80M for ATTO-2306 Phase 2, and the remainder for earlier pipeline and working capital.
Use of Proceeds verify on EDGAR → -
high
ATTO reported a GAAP net loss of $132.6M for the twelve months ended March 31, 2026, and has an accumulated deficit of $129.7M.
Management's Discussion and Analysis verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WLTH 10-Q) is open in full — no account needed.
Partner
Trade ATTO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify